Mitsui Chemicals completes acquisition of Ultradent

Deal completion

Mitsui Chemicals announced completion of its acquisition of Ultradent Products, Inc. on August 14, 2026, after competition and investment approvals were obtained ahead of the originally planned September 2026 timetable. The move makes Ultradent a wholly owned Mitsui Chemicals subsidiary.

Strategic intent

The acquisition strengthens Mitsui’s oral care business in the United States — described in the filing as the world’s largest medical market — and is intended to establish oral care as the third earnings pillar within Life & Healthcare Solutions. Mitsui states the group will pursue a position as the No.2 player in the global dental materials market.

Integration and governance

Post-merger integration steps include transferring oral care business division functionality to the United States as the global headquarters and creating an integrated management structure in which Ultradent’s CEO concurrently serves as CEO of the Kulzer Group and Kulzer’s current CEO becomes Chief Strategy and Integration Officer of MC Dental Holdings America. Mitsui will develop an integrated growth strategy, business plan, KPIs and a synergy roadmap for Ultradent and Kulzer.

Synergies, operations and management views

Mitsui plans to combine its chemical technologies with Ultradent and Kulzer dental-materials capabilities, drive cross-selling across sales networks, broaden product and regional coverage, and target annual synergies exceeding $40 million by fiscal 2030. Company leaders highlighted complementary geographic footprints (Ultradent in the Americas, Kulzer in EMEA), sustained innovation, and expectations that the integration will accelerate global growth and improve profitability.